These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 15791293)
1. Repeated daily injections and osmotic pump infusion of isoproterenol cause similar increases in cardiac mass but have different effects on blood pressure. Hohimer AR; Davis LE; Hatton DC Can J Physiol Pharmacol; 2005 Feb; 83(2):191-7. PubMed ID: 15791293 [TBL] [Abstract][Full Text] [Related]
2. Decreased baroreflex sensitivity in isoproterenol-treated mice with cardiac hypertrophy. Gava AL; Peotta VA; Cabral AM; Meyrelles SS; Vasquez EC Auton Neurosci; 2004 Jul; 114(1-2):47-54. PubMed ID: 15331044 [TBL] [Abstract][Full Text] [Related]
3. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. Zhang GX; Ohmori K; Nagai Y; Fujisawa Y; Nishiyama A; Abe Y; Kimura S J Mol Cell Cardiol; 2007 Apr; 42(4):804-11. PubMed ID: 17350036 [TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling. Jia N; Dong P; Huang Q; Jin W; Zhang J; Dai Q; Liu S Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976 [TBL] [Abstract][Full Text] [Related]
5. Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Schmechel A; Grimm M; El-Armouche A; Höppner G; Schwoerer AP; Ehmke H; Eschenhagen T Cardiovasc Res; 2009 Apr; 82(1):100-6. PubMed ID: 19136528 [TBL] [Abstract][Full Text] [Related]
6. Particulate matter inhalation exacerbates cardiopulmonary injury in a rat model of isoproterenol-induced cardiomyopathy. Carll AP; Haykal-Coates N; Winsett DW; Rowan WH; Hazari MS; Ledbetter AD; Nyska A; Cascio WE; Watkinson WP; Costa DL; Farraj AK Inhal Toxicol; 2010 Apr; 22(5):355-68. PubMed ID: 20121584 [TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Li L; Zhang LK; Pang YZ; Pan CS; Qi YF; Chen L; Wang X; Tang CS; Zhang J Acta Pharmacol Sin; 2006 May; 27(5):527-35. PubMed ID: 16626506 [TBL] [Abstract][Full Text] [Related]
9. Mouse strain-specific differences in cardiac metabolic enzyme activities observed in a model of isoproterenol-induced cardiac hypertrophy. Faulx MD; Chandler MP; Zawaneh MS; Stanley WC; Hoit BD Clin Exp Pharmacol Physiol; 2007; 34(1-2):77-80. PubMed ID: 17201739 [TBL] [Abstract][Full Text] [Related]
10. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Zhang YG; Li YG; Liu BG; Wei RH; Wang DM; Tan XR; Bu DF; Pang YZ; Tang CS Acta Pharmacol Sin; 2007 Jan; 28(1):36-43. PubMed ID: 17184580 [TBL] [Abstract][Full Text] [Related]
11. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. Errami M; Galindo CL; Tassa AT; Dimaio JM; Hill JA; Garner HR J Pharmacol Exp Ther; 2008 Mar; 324(3):1196-203. PubMed ID: 18089841 [TBL] [Abstract][Full Text] [Related]
12. Ultrastructural and electrophysiological alterations during the development of catecholamine-induced cardiac hypertrophy and failure. Mészáros J; Lévai G Acta Biol Hung; 1990; 41(4):289-307. PubMed ID: 2151869 [TBL] [Abstract][Full Text] [Related]
13. L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. Lin Y; Wang LN; Xi YH; Li HZ; Xiao FG; Zhao YJ; Tian Y; Yang BF; Xu CQ Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):124-30. PubMed ID: 18816294 [TBL] [Abstract][Full Text] [Related]
14. Impact of cardiac hypertrophy on arterial and cardiopulmonary baroreflex control of renal sympathetic nerve activity in anaesthetized rats. Flanagan ET; Buckley MM; Aherne CM; Lainis F; Sattar M; Johns EJ Exp Physiol; 2008 Sep; 93(9):1058-64. PubMed ID: 18487313 [TBL] [Abstract][Full Text] [Related]
15. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Jackson EK; Dubinion JH; Mi Z Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624 [TBL] [Abstract][Full Text] [Related]
16. Isoproterenol-induced hypertrophied rat hearts: does short-term treatment correspond to long-term treatment? Takeshita D; Shimizu J; Kitagawa Y; Yamashita D; Tohne K; Nakajima-Takenaka C; Ito H; Takaki M J Physiol Sci; 2008 Jun; 58(3):179-88. PubMed ID: 18462563 [TBL] [Abstract][Full Text] [Related]
17. Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. Anderson M; Moore D; Larson D Perfusion; 2008 Jul; 23(4):231-5. PubMed ID: 19181756 [TBL] [Abstract][Full Text] [Related]
18. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery. Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617 [TBL] [Abstract][Full Text] [Related]
19. Myocardial remodelling induced by repeated low doses of isoproterenol. Mikusová A; Králová E; Tylková L; Novotová M; Stankovicová T Can J Physiol Pharmacol; 2009 Aug; 87(8):641-51. PubMed ID: 19767889 [TBL] [Abstract][Full Text] [Related]
20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]